Zhang Yong, Toneri Makoto, Ma Huaiyu, Yang Zhijian, Bouvet Michael, Goto Yusuke, Seki Naohiko, Hoffman Robert M
AntiCancer Inc., San Diego, California.
Department of Surgery, University of California San Diego, San Diego, California.
J Cell Biochem. 2016 Nov;117(11):2546-51. doi: 10.1002/jcb.25547. Epub 2016 Sep 2.
There are two major types of mouse xenograft models of cancer: subcutaneous implantation and orthotopic implantation. Subcutaneous transplant models are widely used with both cancer cell lines and human-tumor specimens. Recently, subcutaneous models of patient tumors, termed patient-derived xenographs (PDX) have become highly popular and have acquired such names as "Avatar" and "Xenopatients." However, such s.c. models rarely metastasize and are therefore not patient-like. In contrast, orthotopic models have the capability to metastasize. If intact fragments of tumor tissue are implanted by surgical orthotopic implantation (SOI), the metastatic potential can match that of the donor patient. The present study images in real time, using green fluorescent protein (GFP) expression, the very different tumor behavior at the orthotopic and subcutaneous sites of human prostate cancer PC-3 in athymic nude mice. By day-2 after tumor implantation, the orthotopic tumor is already highly vascularized and the cancer cells have begun to migrate out of the tumor. In contrast, the subcutaneous tumor only begins to be vascularized by day-3 and cells do not migrate from the tumor. Angiogenesis is much more extensive in the orthotopic tumor throughout the 2-week observation period. The orthotopic PC-3-GFP tumor progresses very rapidly and distinct metastasis have appeared in lymph nodes by day-3 which rapidly appear in many areas of the abdominal cavity including portal lymph nodes by day-7. At day-14, no invasion or metastasis was observed with the s.c. tumor even when the animal was extensively explored. These results explain why orthotopic tumors mimimc clinical metastatic tumors in nude mice and why subcutaneous tumors do not. J. Cell. Biochem. 117: 2546-2551, 2016. © 2016 Wiley Periodicals, Inc.
皮下植入和原位植入。皮下移植模型广泛应用于癌细胞系和人肿瘤标本。最近,患者肿瘤的皮下模型,即所谓的患者来源异种移植瘤(PDX)变得非常流行,并获得了“阿凡达”和“异种患者”等名称。然而,这种皮下模型很少发生转移,因此不太像患者情况。相比之下,原位模型具有转移能力。如果通过手术原位植入(SOI)植入完整的肿瘤组织片段,转移潜能可与供体患者的相匹配。本研究利用绿色荧光蛋白(GFP)表达实时成像,观察了人前列腺癌PC-3在无胸腺裸鼠体内原位和皮下部位截然不同的肿瘤行为。肿瘤植入后第2天,原位肿瘤已经高度血管化,癌细胞开始从肿瘤中迁移出来。相比之下,皮下肿瘤直到第3天才开始血管化,细胞也不会从肿瘤中迁移。在整个2周的观察期内,原位肿瘤中的血管生成更为广泛。原位PC-3-GFP肿瘤进展非常迅速,第3天在淋巴结中出现明显转移,到第7天迅速出现在腹腔的许多区域,包括门静脉淋巴结。到第14天,即使对动物进行广泛检查,皮下肿瘤也未观察到侵袭或转移。这些结果解释了为什么原位肿瘤在裸鼠中模拟临床转移性肿瘤,以及为什么皮下肿瘤不会。《细胞生物化学杂志》117:2546 - 2551, 2016。©2016威利期刊公司